Breast cancer screening and treatment in Brazil

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer

Oral paclitaxel with encequidar in metastatic breast cancer

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients

Breast cancer prevention in high-risk post-menopausal women

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer

Preventative effects of anastrozole in post-menopausal women who are at high-risk for developing breast cancer

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients?

Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer